Schwerin Boyle Capital Management’s Pfizer PFE Stock Holding History

Schwerin Boyle Capital Management’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12.8M	Sell	529,743 -14,100	-3%	-$369K	1.56%	21
2026 Q1	$15.3M	Sell	543,843 -40,925	-7%	-$1.09M	1.94%	20
2025 Q4	$14.6M	Sell	584,768 -6,592	-1%	-$166K	1.6%	22
2025 Q3	$15.1M	Sell	591,360 -10,225	-2%	-$252K	1.65%	23
2025 Q2	$14.6M	Sell	601,585 -88,900	-13%	-$2.07M	1.63%	23
2025 Q1	$17.5M	Sell	690,485 -28,940	-4%	-$757K	1.8%	19
2024 Q4	$19.1M	Buy	719,425 +3,700	+0.5%	+$100K	1.96%	17
2024 Q3	$20.7M	Sell	715,725 -59,400	-8%	-$1.73M	2.17%	15
2024 Q2	$21.7M	Buy	775,125 +58,850	+8%	+$1.62M	2.27%	15
2024 Q1	$19.9M	Buy	716,275 +132,050	+23%	+$3.66M	1.98%	17
2023 Q4	$16.8M	Buy	584,225 +12,000	+2%	+$363K	1.88%	19
2023 Q3	$19M	Sell	572,225 -187,750	-25%	-$6.64M	2.23%	16
2023 Q2	$27.9M	Buy	+759,975	New	+$29.6M	2.63%	15

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Schwerin Boyle Capital Management's PFE Position: Q2 2026 in Review

Schwerin Boyle Capital Management reduced its Pfizer (PFE) stake by 2.6% in Q2 2026, selling an estimated $369K and leaving 529,743 shares worth $12.8M. The position accounts for 1.56% of the portfolio, ranked #21.

Schwerin Boyle Capital Management first reported a position in PFE in Q2 2023 and has held it in 13 quarters since. The position peaked at $27.9M in Q2 2023. 2,829 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

Schwerin Boyle Capital Management held 529,743 shares of Pfizer worth $12.8M as of Q2 2026.
Schwerin Boyle Capital Management sold 14,100 Pfizer shares in Q2 2026, an estimated $369K.
Pfizer made up 1.56% of Schwerin Boyle Capital Management's portfolio in Q2 2026, its #21 holding.
Schwerin Boyle Capital Management first reported a position in Pfizer in Q2 2023 and has held it in 13 quarters since.
Schwerin Boyle Capital Management's Pfizer position peaked at $27.9M in Q2 2023.
2,829 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Schwerin Boyle Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.